Novolyze intensifies its growth momentum

Novolyze experienced a significant growth in 2016, notably due to the successful launch of SurroNov dry, ready-to-use surrogates for use during in-plant preventive control validation studies. Novolyze's range of SurroNov surrogates are developed and commercially manufactured to replicate the inactivation of foodborne pathogens such as Salmonella , Listeria monocytogenes , Cronobacter sakazakii and E. coli. The commercialization of this range of innovative surrogate microorganisms has led to significant contracts with leading  food industry manufacturers who recognize they are able to perform in-plant preventive control validations quicker and more efficiently by using SurroNov surrogates.

Bullish growth is strongly driven by the enforcement of new international food safety regulations, including US FDA Food Safety Modernization Act (FSMA). Novolyze's portfolio of products and services provides food safety professionals with cutting-edge solutions to comply with major provisions of these new regulations, including FSMA's requirement to validate the efficacy of preventive controls for microbial hazards of concern.

Novolyze 2016 Highlights:

-Global launch of SurroNov range of surrogate microorganisms and NovoConsult range of process validation services

-Strong investments, including the opening of Novolyze's new R&D facilities, and deployment the NovoGate technological platform

-Intensification of Novolyze's presence in the US

Novolyze announced they will keep investing in 2017 to bring new innovative solutions to their partners. The company plans to release new strains of surrogate microorganisms and diversify its activities to cover a broader perimeter of food products and preventive controls. Novolyze also announced the commercial launch of a new connected service, ValidationOnDemand (VOD). VOD improves the daily verification of industrial preventive controls. The main feature is real-time analysis of time and temperature processing parameters validated using SurroNov surrogate microorganisms.

Karim-Franck Khinouche, CEO of Novolyze remarks, "The commercial launch of SurroNov range of surrogates in 2016 has been very successful and based on industry feedback we are confident that we will also reach our 2017 objectives. Our talented team will continue to imagine and develop innovative services and inspired ways of doing business in order to uphold our commitment of bringing new food safety solutions to the industry. Additionally, in early 2017, we plan to open Novolyze's capital with a fundraising campaign of several million dollars."

About Novolyze:  Novolyze is a food biotechnology company offering a portfolio of products and services to help the food industry comply with major international Food Safety regulations, such as the Food Safety Modernization Act (FSMA) in the US. Novolyze's research has mainly focused on evaluating the inactivation kinetics of foodborne pathogens and identifying suitable surrogate microorganisms to help the food industry perform in-plant Process Challenge Tests. Novolyze surrogate microorganisms are presented in the form of a dry and ready-to-use powder. They can be safely used in-plant to validate the efficacy of a process on the destruction of pathogens. Novolyze currently has offices in the US (Cambridge, MA) and in Europe (Dijon, France).

Karim-Franck KHINOUCHE - Président T (France) : +33 695 285 122 kf@novolyze.com